{"id":"onexton-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Peeling"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, targeting Cutibacterium acnes (formerly Propionibacterium acnes). Benzoyl peroxide acts as an oxidizing agent that kills bacteria and helps prevent antibiotic resistance. Together, they provide synergistic antimicrobial and anti-inflammatory effects on acne lesions.","oneSentence":"Onexton is a topical combination gel containing clindamycin and benzoyl peroxide that reduces acne by killing bacteria and decreasing sebum production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:21.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT02578043","phase":"PHASE1","title":"A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":844},{"nctId":"NCT01015638","phase":"PHASE4","title":"Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":36},{"nctId":"NCT01915732","phase":"PHASE3","title":"A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Acne Vulgaris","enrollment":1018},{"nctId":"NCT00964223","phase":"PHASE4","title":"A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":933,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clindamycin, BPO","Clindamycin/benzoyl peroxide gel"],"phase":"phase_3","status":"active","brandName":"Onexton™ Gel","genericName":"Onexton™ Gel","companyName":"Sun Pharmaceutical Industries, Inc.","companyId":"sun-pharmaceutical-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Onexton is a topical combination gel containing clindamycin and benzoyl peroxide that reduces acne by killing bacteria and decreasing sebum production. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}